Innate Pharma (IPHA) Q4 2025 earnings review
Revenue Collapses as Cash Runway Triggers Going Concern Warning
Innate Pharma's financial position is deteriorating rapidly. Full-year revenue plunged 55% to €9.0M as historic collaboration milestones from Sanofi and AstraZeneca dried up. While management executed a 12% deceleration in total operating expenses, the lack of top-line cash generation caused the balance sheet to degrade severely. Cash and investments halved to €44.8M, forcing the company to issue a formal going concern warning. Management expects cash to last only until the end of Q3 2026, making the initiation of their lead Phase 3 asset (Lacutamab) entirely contingent on successfully securing immediate, non-dilutive partnering or royalty financing.
🐂 Bull Case
The AstraZeneca-partnered Monalizumab Phase 3 trial (PACIFIC-9) is fully enrolled and on track for an H2 2026 readout, providing a massive, fully-funded catalyst. Meanwhile, early Phase 1 data for proprietary ADC IPH4502 shows promising anti-tumor activity.
The company has taken decisive action to preserve cash, successfully reducing R&D expenses by 16% and SG&A by 1.6%, while securing a collective agreement for a redundancy plan that will complete in H1 2026.
🐻 Bear Case
With only €44.8M in cash and an operating cash burn of €42M+ per year, the company lacks the capital to independently fund its lead proprietary program. The going concern warning severely limits negotiating leverage with potential partners.
Collaboration revenues collapsed 78% YoY to just €2.8M. Previously lucrative agreements (like the Monalizumab upfront) are now fully recognized, leaving the income statement barren.
⚖️ Verdict: 🔴🔴
Highly Bearish. Despite encouraging clinical progress, the overriding story is the balance sheet. A clinical-stage biotech issuing a going concern warning while trying to fund a Phase 3 trial presents extreme dilution or distressed-sale risks for equity holders.
Key Themes
Going Concern & Accelerated Cash Burn
Management's assertion of 'strong execution across our portfolio' is heavily contradicted by a severe liquidity crisis. The company added a formal going concern warning to its financials as cash plummeted from €91.1M to €44.8M. Operating cash burn accelerated significantly to €52.8M (up from €6.9M in 2024, which was artificially buoyed by legacy tax refunds and a €15M Sanofi upfront). The remaining runway only extends to Q3 2026.
Collaboration Revenues Reversing
The company hit a structural revenue cliff. Total revenue is reversing, driven by a 78% plunge in collaboration revenue (down to €2.8M). Monalizumab revenue recognition dropped from €4.4M in 2024 to €0.2M in 2025 and is now fully depleted. The 2016 Sanofi agreement revenue dropped from €4.0M to zero. Innate is now entirely dependent on securing new, unannounced partnerships to generate top-line cash.
Restructuring and Pipeline Pruning
To artificially extend its runway, Innate is aggressively pruning its pipeline. The Phase 1/2 study for IPH6501 (ANKET anti-CD20) has been officially discontinued. Sanofi also deprioritized SAR'514 (ANKET anti-BCMA). Furthermore, Innate booked €2.9M in provisions for a Workforce Restructuring Plan that is reducing total headcount, signaling a contraction in the company's operational bandwidth.
IPH4502 Validation in Hard-to-Treat Tumors
Innate's proprietary Topo I-based Nectin-4 ADC (IPH4502) is a critical growth driver. Initial Phase 1 dose-finding shows preliminary anti-tumor activity with a favorable safety profile, specifically in heavily pre-treated urothelial cancer patients who have already failed standard-of-care enfortumab vedotin. This validates the exatecan-payload hypothesis and supports best-in-class positioning.
Monalizumab Phase 3 Catalyst
The AstraZeneca-partnered PACIFIC-9 Phase 3 trial remains stable and fully enrolled. Evaluating durvalumab in combination with monalizumab in Stage III NSCLC, this trial is tracking toward an H2 2026 data readout. Because it is externally funded, it represents a massive, free catalyst for Innate's equity.
Lacutamab Regulatory Clearances Achieved
Despite financing hurdles, the regulatory pathway for Lacutamab in CTCL is accelerating. The FDA granted Breakthrough Therapy Designation in February 2025 and cleared the Phase 3 TELLOMAK-3 protocol with no further comments. The trial design explicitly allows for a potential Accelerated Approval pathway in Sézary syndrome.
Other KPIs
A 16% deceleration in spend YoY (down from €52.0M). This reflects disciplined cost control, specifically lower direct costs related to more mature clinical development programs and reduced CMC/toxicology activities for IPH4502, partially offset by €2.3M in workforce restructuring charges.
Stable but slightly declining (down 17% from €7.5M in 2024). The drop is due to a lower base of eligible R&D expenses, driven by fully amortized intangible assets and the exclusion of patent-related expenses under new French Finance Law applicable since February 2025.
Guidance
Decelerating. Prior guidance from late 2023/early 2024 suggested runway through the end of 2025, but given the lack of new upfront milestone cash, the absolute timeline is now critically tight. Substantial doubt exists about the company's ability to operate past September 2026 without a major transaction.
Stable timeline target, but heavily conditional. Management explicitly stated this initiation is completely subject to ongoing negotiations for pharma partnering and royalty structure financing.
Stable. AstraZeneca continues to guide for data in the second half of 2026, which aligns directly with the exhaustion of Innate's current cash runway.
Key Questions
Fallback Plan for Lacutamab
If negotiations for non-dilutive royalty financing or pharma partnerships fall through, what is the contingency plan for the Lacutamab Phase 3 trial? Will the asset be shelved?
Monalizumab Milestones
Can you quantify the specific milestone payments Innate is eligible to receive upon a successful data readout for the PACIFIC-9 trial in H2 2026?
ANKET Platform Viability
With the discontinuation of IPH6501 and Sanofi's deprioritization of SAR'514, how should investors view the forward-looking commercial viability of the ANKET platform?
ATM Utilization
You have a $75M At-The-Market facility that remains entirely untouched. Given the going concern warning, what are the parameters or minimum price thresholds that would trigger you to start utilizing this equity line?